CoChat

Medical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide

Pedroncelli, Alberto M. · 2010 · Neuroendocrinology
Cited by 39

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Cushing’s disease is Cushing’s syndrome caused by an adrenocorticotropic hormone-secreting pituitary adenoma and, in the absence of adequate treatment, can be fatal. Cushing’s disease represents an unmet medical need, with no approved medical therapies. Pasireotide is a novel multi-receptor-targeted somatostatin analogue with high affinity for sst 1,2,3 and sst 5. Compared with octreotide, pasireotide has an in vitro binding affinity 40-, 30- and 5-fold higher for sst 5, sst 1 and sst 3, respectively, and 2-fold lower for sst 2. Adrenocorticotropic hormone-secreting pituitary adenomas predominantly express sst 5, followed by sst 2 and sst 1, suggesting that pasireotide may be effective in the treatment of Cushing’s disease. In a 15-day phase II trial of pasireotide 600 µg s.c. b.i.d. in patients with de novo or persistent/recurrent Cushing’s disease, 22 of 29 patients (76%) achieved reduced urinary free cortisol (UFC) levels, 5 of whom (17%) achieved normalized UFC. Patients who achieved normalized UFC had a significantly greater reduction in serum cortisol than those who did not (p = 0.04), and minimum pasireotide plasma concentrations appeared to be higher in responders. Based on these results, a randomized, double-blind phase III study comparing pasireotide 600 µg b.i.d. and 900 µg b.i.d. was initiated and is ongoing. This is the largest ever phase III study in patients with Cushing’s disease. The primary end point of this study is normalization of UFC after 6 months of treatment. Finally, preliminary results from a study on 17 patients with Cushing’s disease suggest that the combined use of pasireotide, cabergoline and low-dose ketoconazole may have additive beneficial effects in the medical treatment of Cushing’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000314352

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 39

Metadata

Authors
Pedroncelli, A. M.
Venue
Neuroendocrinology
Publisher
S. Karger AG
Published
2010
Volume
92
Issue
Suppl. 1
Pages
120-124
ISSN
  • 0028-3835 (ISSN-L)
  • 1423-0194
OpenAlex
W2044656399
Cited by
39
References
5
FWCI
3.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide. https://app.cochat.ai/papers/10.1159/000314352
The paper
Pedroncelli, A. M. (2010). Medical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide. Neuroendocrinology. https://doi.org/10.1159/000314352

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.